Publications

  1. Patarroyo-Rodriguez L, Vande Voort JL, Kung S, Brown SK, Cavalcanti S, Ritter MJ, Singh B. Non-Cardiac Chest Pain and Hypertensive Urgency During Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression Journal of Clinical Psychopharmacology. 2024.
  2. Lewis CP, Nakonezny PA, Sonmez AI, Ozger C, Garzon JF, Camsari DD, Yuruk D, Romanowicz M, Shekunov J, Zaccariello MJ, Vande Voort JL, Croarkin PE. A Dose-Finding, Biomarker Validation, and Effectiveness Study of Transcranial Magnetic Stimulation for Adolescents With Depression. J Am Acad Child Adolesc Psychiatry. 2024 Sep 6 Epub 2024 Sept 06
    View PubMed
  3. Miola A, Ercis M, Pazdernik VK, Fuentes Salgado M, Ortiz-Orendain J, Gardea-Resendez M, Gruhlke PM, Michel I, Bostwick JM, McKean AJ, Vande Voort JL, Ozerdem A, Frye MA. Association between exposure to antidepressants and stimulants and age at onset of mania or psychosis: A retrospective population-based cohort study. Eur Neuropsychopharmacol. 2024 Sep 2; 89:15-23 Epub 2024 Sept 02
    View PubMed
  4. Patarroyo-Rodriguez L, Cavalcanti S, Vande Voort JL, Singh B. The Use of Ketamine for the Treatment of Anhedonia in Depression. CNS Drugs. 2024 Aug; 38 (8):583-596 Epub 2024 June 23
    View PubMed
  5. Singh B, Kung S, Vande Voort JL. Intravenous (IV) ketamine versus intranasal esketamine for depression- Advantage IV ketamine? J Affect Disord 2024 Jul 1; 356:564-567 Epub 2024 Apr 22
    View PubMed
  6. Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS. Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties. Psychopharmacology (Berl). 2024 May 14 [Epub ahead of print]
    View PubMed
  7. Singh B, Parikh SV, Voort JLV, Pazdernik VK, Achtyes ED, Goes FS, Yocum AK, Nykamp L, Becerra A, Smart L, Greden JF, Bobo WV, Frye MA, Burdick KE, Ryan KA. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial. Psychiatry Res. 2024 May; 335:115829 Epub 2024 Feb 28
    View PubMed
  8. Singh B, Vande Voort JL, Pazdernik VK, Frye MA, Kung S. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine. J Affect Disord. 2024 Apr 15; 351:534-540 Epub 2024 Jan 30
    View PubMed
  9. Cavalcanti S, Lopez OA, Kung S, Vande Voort JL, Somers K, Frye MA, Singh B. A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression. J Clin Psychopharmacol. 2024 Apr 10 [Epub ahead of print]
    View PubMed
  10. Patarroyo-Rodriguez L, Pazdernik V, Vande Voort JL, Kung S, Singh B. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression. J Affect Disord. 2024 Mar 15; 349:272-276 Epub 2024 Jan 08
    View PubMed
  11. Parikh SV, Vande Voort JL, Yocum AK, Achtyes E, Goes FS, Nykamp L, Singh B, Lopez-Vives D, Sera CE, Maixner D, Tarnal V, Severe J, Bartek S, Tye SJ, Rico J, Stoppel CJ, Becerra A, Smart L, Miller CR, Frye MA, Greden JF, Bobo WV. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression. J Affect Disord. 2024 Mar 1; 348:143-151 Epub 2023 Dec 22
    View PubMed
  12. Yuruk D, Ozger C, Garzon JF, Nakonezny PA, Vande Voort JL, Croarkin PE. A retrospective, naturalistic study of deep brain stimulation and vagal nerve stimulation in young patients. Brain Behav. 2024 Mar; 14 (3):e3452
    View PubMed
  13. Nooraeen S, Croarkin PE, Geske JR, Shekunov J, Orth SS, Romanowicz M, Frye MA, Vande Voort JL. High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing. J Child Adolesc Psychopharmacol. 2024 Feb; 34 (1):28-33
    View PubMed
  14. Lynch BA, Lewis CP, Vande Voort JL, Nandakumar AL, Brennan RM, Cole KC, Rackley SJ, Wi CI, Croarkin PE, Romanowicz M. Impact of Family Structure on Adolescent Depression Outcomes in a Collaborative Care Program. J Prim Care Community Health. 2024 Jan-Dec; 15:21501319241291790
    View PubMed
  15. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164. Pharmaceuticals (Basel). 2023 Nov 7; 16 (11) Epub 2023 Nov 07
    View PubMed
  16. Romanowicz M, Croarkin KS, Elmaghraby R, Skime M, Croarkin PE, Vande Voort JL, Shekunov J, Athreya AP. Machine Learning Identifies Smartwatch-Based Physiological Biomarker for Predicting Disruptive Behavior in Children: A Feasibility Study. J Child Adolesc Psychopharmacol. 2023 Nov; 33 (9):387-392
    View PubMed
  17. Betcher HK, Bommersbach TJ, Perossa BA, Larrabee B, Croarkin PE, Romanowicz M, Vande Voort JL, McKean AJ. Adult Outcomes of Children With Reactive Attachment Disorder in a Non-Institutionalized Sample. J Clin Psychiatry. 2023 Oct 18; 84 (6)
    View PubMed
  18. Doruk Camsari D, Lewis CP, Sonmez AI, Ozger C, Fatih P, Yuruk D, Shekunov J, Vande Voort JL, Croarkin PE. Event-Related Potential Markers of Suicidality in Adolescents. Int J Neuropsychopharmacol. 2023 Aug 29; 26 (8):566-575
    View PubMed
  19. Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel). 2023 Aug 16; 16 (8)
    View PubMed
  20. Singh B, Vande Voort JL, Riva-Posse P, Pazdernik VM, Frye MA, Tye SJ. Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression. Biol Psychiatry 2023 Jun 15; 93 (12):e65-e68 Epub 2023 Jan 25
    View PubMed
  21. Mohamed AK, Croarkin PE, Jha MK, Vande Voort JL. Early reduction in irritability is associated with improved outcomes among youth with depression: Findings from the AMOD study. J Affect Disord. 2023 Mar 1; 324:77-81 Epub 2022 Dec 19
    View PubMed
  22. Kumar R, Garzon J, Yuruk D, Hassett LC, Saliba M, Ozger C, Oztosun C, Ahern K, Athreya AP, Singh B, Croarkin PE, Vande Voort JL. Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review. Acta Psychiatr Scand. 2023 Mar; 147 (3):248-256 Epub 2022 Sept 21
    View PubMed
  23. Lapidos A, Lopez-Vives D, Sera CE, Ahearn E, Vest E, Senic I, Vande Voort JL, Frye M, Goes FS, Achtyes E, Greden J, Parikh SV. Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. J Affect Disord. 2023 Feb 15; 323:534-539 Epub 2022 Dec 05
    View PubMed
  24. Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023 Feb 1; 84 (2) Epub 2023 Feb 01
    View PubMed
  25. Ahern KB, Garzon JF, Yuruk D, Saliba M, Ozger C, Vande Voort JL, Croarkin PE. Long-Interval Intracortical Inhibition and the Cortical Silent Period in Youth. Biomedicines. 2023 Jan 30; 11 (2)
    View PubMed
  26. Gardea-Resendez M, Ortiz-Orendain J, Miola A, Fuentes Salgado M, Ercis M, Coombes BJ, Gruhlke PM, Bostwick JM, Michel I, Vande Voort JL, Ozerdem A, McKean A, Frye MA, Taylor-Desir M. Racial differences in pathways to care preceding first episode mania or psychosis: a historical cohort prodromal study. Front Psychiatry. 2023; 14:1241071 Epub 2023 Sept 04
    View PubMed
  27. Yuruk D, Ozger C, Garzon JF, Leffler JM, Shekunov J, Vande Voort JL, Zaccariello MJ, Nakonezny PA, Croarkin PE. Sequential bilateral accelerated theta burst stimulation in adolescents with suicidal ideation associated with major depressive disorder: Protocol for a randomized controlled trial. PLoS One. 2023; 18 (4):e0280010 Epub 2023 Apr 13
    View PubMed
  28. Athreya AP, Vande Voort JL, Shekunov J, Rackley SJ, Leffler JM, McKean AJ, Romanowicz M, Kennard BD, Emslie GJ, Mayes T, Trivedi M, Wang L, Weinshilboum RM, Bobo WV, Croarkin PE. Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. J Child Psychol Psychiatry. 2022 Nov; 63 (11):1347-1358 Epub 2022 Mar 15
    View PubMed
  29. Singh B, MahmoudianDehkordi S, Voort JLV, Han X, Port JD, Frye MA, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium (MDPMC). Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res. 2022 Aug; 314:114655 Epub 2022 May 28
    View PubMed
  30. Zhang CY, Voort JLV, Yuruk D, Mills JA, Emslie GJ, Kennard BD, Mayes T, Trivedi M, Bobo WV, Strawn JR, Athreya AP, Croarkin PE. A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. J Child Adolesc Psychopharmacol. 2022 Jun; 32 (5):278-287
    View PubMed
  31. Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
    View PubMed
  32. Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
    View PubMed
  33. Singh B, Port JD, Pazdernik V, Coombes BJ, Vande Voort JL, Frye MA. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study. Psychiatry Res Neuroimaging 2022 Mar; 320:111432 Epub 2021 Dec 24
    View PubMed
  34. Nunez NA, Coombes BJ, Romo-Nava F, Bond DJ, Vande Voort J, Croarkin PE, Leibman N, Gardea Resendez M, Veldic M, Betcher H, Singh B, Colby C, Cuellar-Barboza A, Prieto M, Moore KM, Ozerdem A, McElroy SL, Frye MA, Biernacka JM. Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. Front Psychiatry. 2022; 13:884217 Epub 2022 Apr 14
    View PubMed
  35. Vande Voort JL, Orth SS, Shekunov J, Romanowicz M, Geske JR, Ward JA, Leibman NI, Frye MA, Croarkin PE. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. J Am Acad Child Adolesc Psychiatry. 2022 Jan; 61 (1):46-55 Epub 2021 June 05
    View PubMed
  36. Nunez NA, Sola C, Kung S, Singh B, Ozerdem A, Veldic M, Croarkin PE, Moore KM, Betcher HK, Vande JL, Geske JR, Biernacka JM, Rummans TA, Bahn RS, Frye MA. Deiodinase variation and liothyronine treatment interaction to accelerate ECT response in major depression: Pilot data and implications for thyroid pharmacogenomic testing in mood disorders Personalized Medicine in Psychiatry. 2021; 29-30.
  37. Shekunov J, Lewis CP, Vande Voort JL, Bostwick JM, Romanowicz M. Clinical Characteristics, Outcomes, Disposition, and Acute Care of Children and Adolescents Treated for Acetaminophen Toxicity. Psychiatr Serv. 2021 Jul 1; 72 (7):758-765 Epub 2021 Apr 23
    View PubMed
  38. Singh B, Port JD, Voort JLV, Coombes BJ, Geske JR, Lanza IR, Morgan RJ, Frye MA. A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. Psychiatry Res. 2021 Jul; 301:113953 Epub 2021 Apr 20
    View PubMed
  39. Parikh SV, Lopez D, Vande Voort JL, Rico J, Achtyes E, Coryell W, Goddard A, Goes F, Greden JF, Singh B, Kaplin A, Frye MA, Maixner D, Watson B, Drake K, Tarnal V, Riva-Posse P, Bobo WV, Bio-K Study Team Team. Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacol Bull. 2021 Jun 1; 51 (3):109-124
    View PubMed
  40. Hu Y, Kung S, Ozerdem A, Vande Voort JL, Singh B, McDonald WM, Riva-Posse P, Frye MA. Hypomania associated with high dose ketamine treatment. Bipolar Disord. 2021 Jun; 23 (4):426-428 Epub 2021 Feb 24
    View PubMed
  41. Fatih P, Kucuker MU, Vande Voort JL, Doruk Camsari D, Farzan F, Croarkin PE. A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders. Front Psychiatry. 2021; 12:678088 Epub 2021 June 02
    View PubMed
  42. Nunez NA, Joseph B, Pahwa M, Seshadri A, Prokop LJ, Kung S, Schak KM, Vande Voort JL, Frye MA, Singh B. An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2020 Sep 14; 50 (4):137-163
    View PubMed
  43. Ballard ED, Farmer CA, Shovestul B, Vande Voort J, Machado-Vieira R, Park L, Merikangas KR, Zarate CA Jr. Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study. Bipolar Disord. 2020 May; 22 (3):245-254 Epub 2019 Dec 09
    View PubMed
  44. Sonmez AI, Kucuker MU, Kolla BP, Lewis CP, Kolla BP, Doruk Camsari D, Vande Voort JL, Schak KM, Kung S, Croarkin PE. Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8; 97:109763 Epub 2019 Oct 18
    View PubMed
  45. Bieber ED, Vande Voort JL, Croarkin PE, VON Drehle CT, Simon SM, Hopp BN, Heil HM, Romanowicz M. Documentation Practices for Transgender Youth Admitted to an Inpatient Psychiatric Unit. J Psychiatr Pract. 2020 Mar; 26 (2):153-159
    View PubMed
  46. Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, Cabello Arreola A, Vande Voort JL, Croarkin P, Moore KM, Biernacka J, McElroy SL, Frye MA. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials. Bipolar Disord. 2020 Mar; 22 (2):109-120 Epub 2020 Jan 07
    View PubMed
  47. Shekunov J, Blacker CJ, Vande Voort JL, Tillema JM, Croarkin PE, Romanowicz M. Immune mediated pediatric encephalitis - need for comprehensive evaluation and consensus guidelines. BMC Neurol. 2020 Feb 3; 20 (1):44 Epub 2020 Feb 03
    View PubMed
  48. Bieber ED, Edelsohn GA, McGee ME, Shekunov J, Romanowicz M, Vande Voort JL, McKean AJS. The Role of Parental Capacity for Medical Decision-Making in Medical Ethics and the Care of Psychiatrically Ill Youth: Case Report. Front Psychiatry. 2020; 11:559263 Epub 2020 Oct 23
    View PubMed
  49. Singh B, Bobo WV, Rasmussen KG, Stoppel CJ, Rico JA Jr, Schak KM, Biernacka JM, Frye MA, Vande Voort JL. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. J Clin Psychiatry 2019 Nov 12; 80 (6)
    View PubMed
  50. Betcher HK, Vande Voort JL, Croarkin PE, Gandhi KD, Shekunov J, Larrabee BR, Limbeck MG, Rummans TA, Romanowicz M. Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls. Prim Care Companion CNS Disord. 2019 Aug 15; 21 (4)
    View PubMed
  51. Bieber ED, Bieber DA, Romanowicz M, Vande Voort JL, Kolla BP, McKean AJS. Recurrent Isolated Sleep Paralysis Following Bupropion Cessation: A Case Report. J Clin Psychopharmacol 2019 Jul-Aug; 39 (4):407-409
    View PubMed
  52. Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S, Lewis CP, Croarkin PE. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res. 2019 Mar; 273:770-781 Epub 2018 Dec 07
    View PubMed
  53. Romanowicz M, Schak KM, Vande Voort JL, Leung JG, Larrabee BR, Palmer BA. Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations. J Pers Disord.. 2019.
    View PubMed
  54. Nandakumar AL, Vande Voort JL, Nakonezny PA, Orth SS, Romanowicz M, Sonmez AI, Ward JA, Rackley SJ, Huxsahl JE, Croarkin PE. Psychometric Properties of the Patient Health Questionnaire-9 Modified for Major Depressive Disorder in Adolescents. J Child Adolesc Psychopharmacol. 2019 Feb; 29 (1):34-40 Epub 2018 Nov 02
    View PubMed
  55. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol. 2019; 10:83 Epub 2019 Feb 19
    View PubMed
  56. Romanowicz M, Vande Voort JL, Shekunov J, Oesterle TS, Thusius NJ, Rummans TA, Croarkin PE, Karpyak VM, Lynch BA, Schak KM. The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. Child Adolesc Psychiatry Ment Health. 2019; 13:5 Epub 2019 Jan 12
    View PubMed
  57. Steinauer LM, Leung JG, Burkey BW, McGrane IR, Letts V, Goren JL, Hoeft DM, Mullen S, Maroney M, Schak KM, Vande Voort JL. A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization. J Child Adolesc Psychopharmacol. 2018 Nov; 28 (9):615-619 Epub 2018 Oct 24
    View PubMed
  58. Markota M, McKean AJ, Romanowicz M, Schak KM, Croarkin PE, Vande Voort JL. Rehospitalization to a child and adolescent psychiatry unit: Role of trauma and bullying. Gen Hosp Psychiatry. 2018 Nov - Dec; 55:10-14 Epub 2018 Aug 30
    View PubMed
  59. Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV, Camsari DD, Schak KM, Port JD, Lewis CP. High-frequency repetitive TMS for suicidal ideation in adolescents with depression. J Affect Disord. 2018 Oct 15; 239:282-290 Epub 2018 July 18
    View PubMed
  60. Lewis CP, Nakonezny PA, Blacker CJ, Vande Voort JL, Port JD, Worrell GA, Jo HJ, Daskalakis ZJ, Croarkin PE. Cortical inhibitory markers of lifetime suicidal behavior in depressed adolescents. Neuropsychopharmacology. 2018 Aug; 43 (9):1822-1831 Epub 2018 Mar 14
    View PubMed
  61. Na PJ, Yaramala SR, Kim JA, Kim H, Goes FS, Zandi PP, Vande Voort JL, Sutor B, Croarkin P, Bobo WV. The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)-9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). J Affect Disord. 2018 May; 232:34-40 Epub 2018 Feb 17
    View PubMed
  62. Shafi RMA, Vande Voort JL, Croarkin PE, Romanowicz M. Parent-Child Interaction Therapy in a Case of Global Developmental Delay and Leukoencephalopathy. Front Psychiatry. 2018; 9:427 Epub 2018 Sept 10
    View PubMed
  63. Romanowicz M, McKean AJ, Vande Voort J. A case of a four-year-old child adopted at eight months with unusual mood patterns and significant polypharmacy. BMC Psychiatry. 2017 Sep 11; 17 (1):330 Epub 2017 Sept 11
    View PubMed
  64. Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, Park LT, Machado-Vieira R, Duncan WC Jr, Zarate CA Jr. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2017 Sep/Oct; 78 (8):1068-1074
    View PubMed
  65. Gonzalez SD, Williams AJ, Blacker CJ, Vande Voort JL, Schak KM, Nemeroff CB, Widge AK, Tohen M. Putative biological predictors of treatment response in bipolar disorders Personalized Medicine in Psychiatry.2017;1:(2):39-58.
  66. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec; 206:300-304. Epub 2016 Sep 12.
    View PubMed
  67. Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depress Anxiety. 2016 Aug; 33 (8):698-710 Epub 2016 Apr 06
    View PubMed
  68. Jameson ND, Sheppard BK, Lateef TM, Vande Voort JL, He JP, Merikangas KR. Medical Comorbidity of Attention-Deficit/Hyperactivity Disorder in US Adolescents. J Child Neurol. 2016 Jun 22;
    View PubMed
  69. Ballard ED, Vande Voort JL, Luckenbaugh DA, Machado-Vieira R, Tohen M, Zarate CA. Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. Bipolar Disord. 2016 Jun; 18 (4):363-72 Epub 2016 May 27
    View PubMed
  70. Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, Niciu MJ, Furey ML, Duncan WC Jr, Zarate CA Jr. Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2016 Jun; 77: (6)825-31.
    View PubMed
  71. Vande Voort JL, Singh A, Bernardi J, Wall CA, Swintak CC, Schak KM, Jensen PS. Treatments and Services Provided to Children Diagnosed with Bipolar Disorder. Child Psychiatry Hum Dev. 2016 Jun; 47 (3):494-502
    View PubMed
  72. McKean AJ, Vande Voort JL, Bostwick JM. Re: "Telepharmacotherapy for Child and Adolescent Psychiatric Patients" by Cain and Sharp (J Child Adolesc Psychopharm 2016;26:221-228). J Child Adolesc Psychopharmacol 2016 Apr; 26 (3):305 Epub 2016 Mar 30
    View PubMed
  73. Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, Palmer BA, Frye MA. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry. 2016 Mar 1; 173 (3):215-8
    View PubMed
  74. Lewis CP, Nakonezny PA, Ameis SH, Vande Voort JL, Husain MM, Emslie GJ, Daskalakis ZJ, Croarkin PE. Cortical inhibitory and excitatory correlates of depression severity in children and adolescents. J Affect Disord. 2016 Jan 15; 190:566-575 Epub 2015 Oct 28
    View PubMed
  75. Lewis CP, Port JD, Frye MA, Vande Voort JL, Ameis SH, Husain MM, Daskalakis ZJ, Croarkin PE. An Exploratory Study of Spectroscopic Glutamatergic Correlates of Cortical Excitability in Depressed Adolescents. Front Neural Circuits. 2016; 10:98 Epub 2016 Nov 29
    View PubMed
  76. Ballard ED, Luckenbaugh DA, Richards EM, Walls TL, Brutsche NE, Ameli R, Niciu MJ, Vande Voort JL, Zarate CA Jr. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015 Sep; 68:68-73.
    View PubMed
  77. Iadarola N, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent A, Machado-Vieira R, Zarate CA Jr. Ketamine and other NMDA receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015 May; 6(3):97-114.
  78. Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast. 2015; 2015:858251 Epub 2015 June 07
    View PubMed
  79. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey M, Zarate CA Jr. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014 Nov; 58:161-6.
  80. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey M, Zarate CA Jr. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res. 2014 Nov; 58:197-9.
  81. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014 Sep; 75(9):e932-8.
  82. Vande Voort JL, He JP, Jameson ND, Merikangas KR. Impact of the DSM-5 attention-deficit/hyperactivity disorder age-of-onset criterion in the US adolescent population. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):736-44.
  83. Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 2014 Jul; 47(4-5):141-142.
  84. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ME, Zarate CA Jr. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol.2014 Oct 31;18:(1):
  85. Ballard ED, Ionescu DF, Vande Voort JL, Slonena EE, Franco-Chaves JA, Zarate CA Jr, Grillon C. Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. J Affect Disord. 2014 Jun; 162:34-8.
  86. Coburn JA, Vande Voort JL, Lahr BD, Van Dyke CT, Kroning CM, Wu TT, Gandhi MJ, Murray JA. Human leukocyte antigen genetics and clinical features of self-treated patients on a gluten-free diet. J Clin Gastroenterol. 2013 Nov-Dec; 47 (10):828-33
    View PubMed
  87. Vande Voort JL, Swintak CC, Wall CA, Rasmussen KG Jr. Methohexital-induced seizures during electroconvulsive therapy. J ECT. 2013 Mar; 29 (1):e4-5
    View PubMed
  88. Vande Voort JL, Svecova J, Jacobson AB, Whiteside SP. A retrospective examination of the similarity between clinical practice and manualized treatment for childhood anxiety disorders. Cognitive and Behavioral Practice. 2010; 17(3):322-8.
  89. Sim LA, Homme JH, Lteif AN, Vande Voort JL, Schak KM, Ellingson J. Family functioning and maternal distress in adolescent girls with anorexia nervosa. Int J Eat Disord. 2009 Sep; 42(6):531-9.
    View PubMed
  90. Vande Voort JL, Murray JA, Lahr BD, Van Dyke CT, Kroning CM, Moore SB, Wu TT. Lymphocytic duodenosis and the spectrum of celiac disease. Am J Gastroenterol. 2009 Jan; 104 (1):142-8
    View PubMed
  91. Krych EH, Vande Voort JL. Medical students speak: a two-voice comment on learning professionalism in medicine. Clin Anat. 2006 Jul; 19(5):415-8.
    View PubMed